Commentary Open Access
Volume 4 | Issue 1 | DOI: https://doi.org/10.46439/signaling.4.106
Epithelial transfer variability of the tyrosine kinase inhibitors of epithelial-growth factor receptor: Implications for pharmacokinetic resistance in NSCLC
Carmelo Tibaldi1,*, Miriam Caccese1, Editta Baldini1
- 1Department of Oncology, Azienda USL Toscana Nord ovest (ATNO), S.Luca Hospital, Lucca, Italy
Corresponding Author
Carmelo Tibaldi, carmelo.tibaldi@uslnordovest.toscana.it
Received Date: July 31, 2025
Accepted Date: June 29, 2026
Tibaldi C, Caccese M, Baldini E. Epithelial transfer variability of the tyrosine kinase inhibitors of epithelial-growth factor receptor: Implications for pharmacokinetic resistance in NSCLC. Cell Signal. 2026;4(1):111-114.
Copyright: © 2026 Tibaldi C, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
The value of EGFR in individualized treatment for brain metastases in non-small cell lung cancer
The epidermal growth factor receptor (EGFR) is a member of the ErbB family. It is involved in biological processes such as cell proliferation, angiogenesis, inhibition of apoptosis, adhesion, metastasis, and is associated with the progression of lung cancer [1-3].
Network-based poly-pharmacological study sheds light on effective active constituents in Compound Kushen Injection preparations against lung cancer
Traditional Chinese Medicine (TCM), the world’s oldest known herbal medicine, has long been used in several Asian countries. Emerging evidence has demonstrated their effectiveness and safety in the treatment of various diseases, ranging from mild flu to severe cancers. A great number of patients have benefited by receiving TCM therapies. However, due to the complex chemical compositions of TCM, which could produce highly complex compound-protein binding interactions, the molecular mechanisms underlying the pharmacological actions of TCM still remain poorly understood. Specifically, it is difficult to identify and isolate the effective constituents from the mixture of many compounds, even the therapeutic targets are known.
Epithelial transfer variability of the tyrosine kinase inhibitors of epithelial-growth factor receptor: Implications for pharmacokinetic resistance in NSCLC
The discovery of Tyrosine Kinase inhibitors (TKIs) of Epidermal Growth Factor Receptor (EGFR) represented a significant revolution for the treatment of non-small cell lung cancer (NSCLC). In fact, they are administered orally, on an out-patient basis, at fixed dose, and independently of weight, height, sex or age.